We thank Bandera et al for their insightful comments on our recent publication demonstrating synergistic effects of exercise parameters and cardiac biomarkers, such as brain natriuretic peptide, for risk prediction in ambulatory and euvolemic patients with advanced heart failure. 1 We agree with the assumption that levels of brain natriuretic peptide in this cohort might reflect different degrees of myocardial load and associated wall stress and are only partially related to overall functional capacity. In the subset of patients with available invasive hemodynamic data, we could confirm that parameters of right ventricular dysfunction (such as increased right atrial pressure) and group II pulmonary hypertension (mean pulmonary artery pressure) are associated with reduced exercise tolerance (r=−0.23; P=0.005 and r=−0.27; P=0.024, respectively) and increased brain natriuretic peptide levels (r=0.4; P<0.0001 and r=0.27; P=0.002, respectively). These findings support the statement by Bandera et al that markers of right ventricular dysfunction and pulmonary artery hypertension contribute to impaired exercise performance and increased circulating brain natriuretic peptide. These parameters might, therefore, be additional determinants during evaluation of patients for heart transplantation and its subsequent timing.
Response to Letter Regarding Article, "Value of Peak Exercise Oxygen Consumption Combined With B-Type Natriuretic Peptide Levels for Optimal Timing of Cardiac Transplantation"
We thank Bandera et al for their insightful comments on our recent publication demonstrating synergistic effects of exercise parameters and cardiac biomarkers, such as brain natriuretic peptide, for risk prediction in ambulatory and euvolemic patients with advanced heart failure. 1 We agree with the assumption that levels of brain natriuretic peptide in this cohort might reflect different degrees of myocardial load and associated wall stress and are only partially related to overall functional capacity. In the subset of patients with available invasive hemodynamic data, we could confirm that parameters of right ventricular dysfunction (such as increased right atrial pressure) and group II pulmonary hypertension (mean pulmonary artery pressure) are associated with reduced exercise tolerance (r=−0.23; P=0.005 and r=−0.27; P=0.024, respectively) and increased brain natriuretic peptide levels (r=0.4; P<0.0001 and r=0.27; P=0.002, respectively). These findings support the statement by Bandera et al that markers of right ventricular dysfunction and pulmonary artery hypertension contribute to impaired exercise performance and increased circulating brain natriuretic peptide. These parameters might, therefore, be additional determinants during evaluation of patients for heart transplantation and its subsequent timing.
Further, we agree that inclusion of cardiopulmonary exercise testing ventilatory and gas exchange variables could potentially improve patient categorization and risk prediction. In line with the insightful assessment by Bandera et al, we hope that our study and subsequent follow-up studies will allow to establish a novel multiparametric approach to define indications and timing for heart transplantation.
Such approach should include clinical characteristics, including the use of mechanical circulatory support, exercise performance, circulating biomarkers, and invasive hemodynamics to define risk and benefit in this challenging patient population with advanced heart failure. 2
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